Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

CPT-11 Recommended as Standard in 5-FU Resistant Colorectal Cancer

July 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

LOS ANGELES--Irinotecan (Camptosar), also known as CPT-11, should be standard therapy for patients whose metastatic colorectal cancer has become resistant to fluorouracil (5-FU), David Cunningham, MD, said at the plenary session of the American Society of Clinical Oncology (ASCO) annual meeting. Dr. Cunningham is head of the Gastrointestinal Cancer Unit, Royal Marsden Hospital, London, UK.

LOS ANGELES--Irinotecan (Camptosar), also known as CPT-11, should be standard therapy for patients whose metastatic colorectal cancer has become resistant to fluorouracil (5-FU), David Cunningham, MD, said at the plenary session of the American Society of Clinical Oncology (ASCO) annual meeting. Dr. Cunningham is head of the Gastrointestinal Cancer Unit, Royal Marsden Hospital, London, UK.

In a multicenter phase III trial, patients randomized to irinotecan were 2.6 times more likely to be alive at 1 year following treatment and lived significantly longer than those who received only best supportive care.

"We found that the quality of life of patients on the CPT-11 arm of the trial was significantly better and also that they had fewer symptoms related to the underlying cancer," Dr. Cunningham said. "The findings are so impressive that we would no longer consider best supportive care to be an acceptable treatment option for this population."

Irinotecan, a topoisomerase I inhibitor, is licensed by the FDA for use as second-line therapy in metastatic colorectal cancer, based on a 15% objective response rate seen in pretreated metastatic colorectal cancer patients in a phase II trial.

There has been concern that this improvement might not be sufficient to make the agent a worthwhile option in these patients, in view of the agent’s significant problems with diarrhea.

Thus, Dr. Cunningham and his colleagues initiated this randomized phase III trial to confirm the clinical benefit of irinotecan vs no active anticancer therapy in terms of overall survival in resistant metastatic colorectal cancer.

Inclusion criteria included tumor progression within 6 months of prior 5-FU, no more than two prior 5-FU palliative regimens, and no bulky disease. Patients with poor performance status (PS of 2 or less) were also excluded because studies had shown that irinotecan is not effective in that population.

The trial randomized 279 patients in a 2:1 ratio to either irinotecan, 350 mg/m² every 3 weeks (300 mg/m² if age 70 or more, or PS = 2) plus optimal supportive care, or optimal supportive care alone.

Better Survival

Overall survival rates were significantly better in the patients treated with irino-tecan (see Figure), and the curves began to separate within 2 months of beginning treatment (P =.0001). At 12 months, the odds of death were 2.6 times higher with best supportive care than with irinotecan (36.2% survival for irinotecan vs 13.8% for supportive care).

Multivariate analysis found that the five most important prognostic variables were performance status, weight loss, hemoglobin level, alkaline phosphatase level, and number of involved organs.

"After correcting for all of the major prognostic factors, treatment with CPT-11 continues to have a major, significant impact on the risk of death for this patient population," Dr. Cunningham commented.

More patients in the treatment arm survived without deterioration in performance status, and more had pain-free survival.

"CPT-11 prolongs survival, improves quality of life, and improves control of tumor-related symptoms," Dr. Cun-ningham said. "The results are sufficiently important for us to believe that this represents a new standard of care for second-line treatment of patients with colorectal cancer. When the disease has become resistant to treatment with 5-fluorouracil, patients should be offered CPT-11."

Nearly All Become Resistant

Virtually all patients with metastatic disease eventually become resistant to 5-FU. The effect of irinotecan occurred regardless of prior response to 5-FU.

"Median survival of patients with metastatic colorectal disease is about 12 months. CPT-11 adds an additional 3 months to that," Dr. Cunningham said. "Patients were able to carry on a normal life for much longer."

Irinotecan has a well-known tendency to cause sometimes serious diarrhea and did cause severe diarrhea in about 22% of patients, but Dr. Cunningham said that the diarrhea was readily managed by conventional antidiarrheal agents in this study.

In discussing the study, Michael O’Connell, MD, of the Mayo Clinic, agreed that irinotecan had a highly significant short-term survival effect but pointed out that median survival was prolonged by only 2.7 months and that there was no long-term survival benefit associated with treatment.

However, Dr. O’Connell also noted that the cost of irinotecan is similar to that for other agents used to treat advanced cancer and that the drug is widely available and can be given as outpatient treatment.

He suggested that the dose should perhaps be reduced to 300 mg/m² for patients over age 70 and that the drug might not be appropriate for patients with bulky disease, especially hepatic tumors, or for those who have had prior pelvic radiation and are therefore more susceptible to severe diarrhea.

Articles in this issue

Calling the National Cancer Institute
Six Cycles of AT Found Safe in Advanced Breast Cancer
New Drug Promising in Advanced Pancreatic Cancer
Herceptin/Chemo Effective in Metastatic Breast Cancer
Virtual Reality Exhibit Simulates Cancer Fatigue
New Director of AIDS Research
Exhibit Explores Healing Power of Creating Artwork
Update on Trials of Thrombopoietin for Platelet Recovery
Amifostine Reduces Xerostomia After RT for Head and Neck Cancer
National Survey Documents Gap in Quality of HIV/AIDS Care
Taxotere Improves Survival More than MV in Anthracycline-Resistant Breast Cancer
Stomach Cancer Susceptibility Gene Found in the Maori
Study Shows 6-Month Chemo Regimen Should Be New Colon Cancer Standard
Nurses Urged to Be Alert for Depression in Cancer Patients
Androgen Ablation Added to RT Improves Outcome in Locally Advanced Prostate Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance–Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance–guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Related Content

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance–Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance–guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.